Trial Profile
Effect and Safety of Semaglutide 2.4 mg Once-weekly as Adjunct to Intensive Behavioural Therapy in Subjects With Overweight or Obesity
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Acronyms STEP 3
- Sponsors Novo Nordisk
- 01 Dec 2022 Results assessing the safety and efficacy of a weekly 2.4-mg subcutaneous injection of semaglutide for chronic weight management in STEPS 1-4 studies, published in the American Journal of Managed Care.
- 04 Nov 2022 Results of pooled analysis from STEP 1 and 3, examining semaglutide treatment response and tolerability by self identified racial and ethnic subgroups, presented at The Obesity Society: ObesityWeek 2022
- 20 Jun 2022 Results assessing adults with overweight/obesity across the Semaglutide Treatment Effect in People with obesity (STEP) 1, 3, and 4 trials published in the Diabetes Care